Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Naldemedine (Primary)
- Indications Constipation; Intestinal disorders
- Focus Adverse reactions
- Sponsors Shionogi
- 14 May 2016 Results presented at the 35th Annual Scientific Meeting of the American Pain Society
- 12 Oct 2011 New trial record